Perhaps, a combination approach with tumor-selective DNA damaging agents (e.g., NQO1-bioactivatable agents, vide infra in Section 6) may overcome this limitation to improve the tumor-selectivity of NAMPT inhibitors by severely depleting the NAD+ needed by PARPs for efficient DNA repair and survival [82,104]. The gene discussed is NAMPT; the disease is neoplasm.